News

3P Biopharmaceuticals makes a significant donation to help Ukraine

The donation is an employee initiative and is supported by the company.
Read more

Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.

Navarra advances in the Comprehensive Strategy for Personalized Medicine with the constitution of the body that will coordinate its execution.
Read more

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director, leading quality control, quality assurance and analytical departments
Read more

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more

Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE

Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021
Read more

3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.
Read more

3P Biopharmaceuticals appoints Diego Bochoeyer as Director of Strategic Development and Supply Chain

3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain.
Read more

3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology

3P Biopharmaceuticals and Precirix NV have signed an agreement for the clinical manufacturing of a camelid single-domain antibody fragment (sdAb), the backbone of Precirix’ next product candidate to enter the clinic.
Read more

3P Biopharmaceuticals receives FDA approval

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.